Dutch Startup Revolutionises Heart Diagnostics with One-Minute Mobile ECG
Amsterdam, Tuesday 23 June 2026
HeartEye secures €1.5 million to bring a groundbreaking mobile ECG recorder to Dutch GPs—cutting hospital referrals by enabling instant, clinical-grade heart scans in under 60 seconds, all without the usual hassle of training or supplies.
The Technology Behind the One-Minute ECG
HeartEye’s mobile 12-lead ECG recorder represents a significant leap in point-of-care diagnostics, capable of generating a full electrocardiogram in under 60 seconds [1]. The device eliminates traditional barriers in primary care settings by removing the need for plaster electrode ordering, extensive staff training, or complex setup procedures [1]. This innovation comes at a critical time for the Dutch healthcare system, where general practitioners (GPs) face increasing pressure to manage cardiovascular risk assessment within their practices rather than referring patients to hospitals [1]. The technology’s clinical-grade accuracy has been designed to meet the stringent requirements of primary care diagnostics while maintaining consumer-friendly accessibility [1].
Funding and Market Validation Strategy
The €1.5 million funding secured on 20 June 2026 marks a pivotal moment for HeartEye’s commercialisation efforts [2]. This capital injection follows the company’s participation in ROM InWest’s GO!-NH Market Readiness Program, where HeartEye focused on product validation and customer segmentation without pursuing medical certification [1]. The funding will support an early access program targeting Dutch GPs, with an ambitious goal of achieving 80% retention among initial users before considering broader market expansion [1]. HeartEye’s founder Tjebbe Tauber emphasised the strategic focus on current business phase: “We have no medical certification yet, so we must prove our product-market fit without being able to sell our product for actual care delivery” [1].
Economic and Healthcare System Impact
HeartEye’s business model addresses multiple pain points in the Dutch healthcare system. The device enables GPs to bill for ECG services directly, potentially reducing costly cardiologist referrals while maintaining remote specialist support [1]. This aligns with broader trends in Benelux digital health, where portable diagnostics are being leveraged to enhance efficiency in overburdened healthcare systems [GPT]. Tauber highlighted the economic realities of healthcare delivery: “Money remains an important factor… but I know what I’m working towards: reducing mortality from heart problems by improving diagnostics while keeping care efficient, affordable and accessible” [1]. The technology’s potential to lower societal healthcare costs comes at a time when cardiovascular disease remains the leading cause of death in the Netherlands, accounting for approximately 27% of all deaths annually [3].
Competitive Landscape and Future Outlook
HeartEye enters a competitive medtech landscape where established players like Philips and GE Healthcare dominate the ECG equipment market [GPT]. However, the startup differentiates itself through its focus on primary care accessibility and rapid deployment capabilities. The Dutch market presents particular advantages for early adoption, given the country’s advanced digital health infrastructure and GP-centric healthcare model [4]. Industry analysts note that successful implementation could position HeartEye as a key player in the €3.2 billion European cardiac monitoring market, which is projected to grow at a compound annual rate of 25.806% through 2030 [5]. The company’s near-term focus remains on achieving CE-marking and validating product-market fit with Dutch GPs before considering expansion to other sectors or international markets [1].